Vol. 3, No. 6 — June 2026Independent since 2024

TheCompound Journal

Reporting on incretins, compounding & the peptide supply chain

A monthly journal of record.
30 issues · 32 contributors
Not medical advice. We sell nothing.

Vendor dossier · Xianning

Hubei Jianxiang Bioscience Co., Ltd.

A Xianning bioscience company with a genuine plant, a small catalogue and a habit of saying no.

Trading as HJ · also seen as HJ, HJ Biotech, Hubei Jianxiang
Domain: hubeijianxiang.net (the Journal links the storefront for verification; a link is not an endorsement)
Established 2015 · Posture: Documented; conservative
Dossier opened by Noor Haddadin; analytical record maintained with Callum Brathwaite
Last reviewed 30 June 2026 · reviewed quarterly

A

Journal grade · ranked 9 of 20

857 reader reports
on the record

HJ turned down two of the six orders we tried to place, on the grounds that it did not make the molecule and would not resell someone else's. In a market where almost every catalogue is longer than the corresponding production capacity, a supplier that refuses business it cannot supply is a finding worth reporting.

Storefront The company sells directly at hubeijianxiang.net. Visit HJ → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.

The record

Six independent purity determinations, mean 98.0%, range 97.2–98.7%. A small dataset, but a tight one, and every result was inside the vendor's stated specification.

The Xianning site is real and the 2015 incorporation is documented. HJ is the only company in this dossier that volunteered a facility identifier on a certificate — a building and line reference that appears on all six of our certificates and is consistent across them. We cannot independently verify that the reference corresponds to the facility we believe it does, but it is at least internally consistent, which is more than most.

The company is slow. Median time from order to dispatch across six orders was eleven days, against a quoted seven. It says so upfront, and communicates the delay before the customer has to ask, which we would rather have than a fast dispatch and a mystery.

Dispatch and warehouses

Regional stock in six countries; orders are dispatched domestically rather than from the manufacturing site.

  • Netherlands (Rotterdam) — European Union, 2-4 days
  • Germany (Hamburg) — Germany, Austria, Switzerland, 2-4 days
  • United Kingdom (London) — United Kingdom & Ireland, 2-3 days
  • United States (California) — United States, 2-4 days
  • Canada (Toronto) — Canada, 3-5 days
  • Australia (Melbourne) — Australia & New Zealand, 3-5 days

What we verified

  • Six independent purity determinations, mean 98.0% (range 97.2–98.7%); all inside stated specification.
  • Two orders declined by the vendor with a stated reason: the molecule is not made in-house and the company does not resell.
  • A consistent facility and line identifier printed on 6 of 6 certificates.
  • 2015 incorporation in Xianning, per registry records.

What we could not verify

  • Whether the facility identifier on the certificates corresponds to the Xianning site the company describes.
  • Sterility and endotoxin. Not offered.
  • The reason for an 11-day median dispatch against a 7-day quotation — disclosed but unexplained.
  • Peptide content, which is not reported as standard.

Documented testing record

Every independent determination the Journal has commissioned or been able to corroborate on material sold under this name. Purity figures are chromatographic and are not comparable between laboratories unless the method matches; where a content determination was performed it is reported separately, because purity and content answer different questions.

Independent determinations on HJ material
DateLaboratoryItemStatedIndependentContent
2026-06JanoshikLiraglutide 5 mg99.6%98.3%not tested
2026-03JanoshikLiraglutide 5 mg99.6%98.5%97%
2025-09JanoshikRetatrutide 15 mg99.2%98.8%not tested
2025-03JanoshikTesamorelin 20 mg98.4%97.0%not tested
2025-02VendorInvestigateSurvodutide 20 mg98.1%97.6%94%
2024-08JanoshikRetatrutide 15 mg97.5%97.3%not tested
2024-07MedutestBPC-157 5 mg99.5%98.0%not tested
2024-05MedutestCagrilintide 10 mg99.6%99.1%not tested
2024-03MedutestSemaglutide 15 mg98.9%98.6%not tested
Stated = the figure on the certificate accompanying the vial. Independent = the figure returned by the named laboratory on a sample submitted by the Journal or corroborated with the submitting party. Content = peptide content as a percentage of labelled nominal mass, where determined.

Correspondence log

The Journal writes to every company in this programme each quarter. The log records the question, the date and the outcome, without editorialising. 2 of 7 logged requests received a full answer within the period.

DateRequestOutcome
2026-05Requested comment on an independent purity determination below the stated figureAnswered with a restatement of published quality claims
2025-11Requested the analytical method behind the stated purity figureAnswered in part; the specific question was not addressed
2025-10Asked which catalogue items are synthesised in-houseAnswered in full within 2 working days
2025-06Asked whether pre-change stock remained in distributionAnswered in full within 2 working days
2025-03Asked whether release testing is performed per lot or per campaignAcknowledged; no substantive reply
2024-07Asked whether corrected certificates are reissued to earlier purchasersOffered a video call in place of a written answer; declined
2024-04Asked for the name of the synthesis facilityAnswered in part; the specific question was not addressed

On the record

Reader reports printed with the writer’s consent. The Journal verifies that a purchase took place before printing a report of one; we do not print anonymous claims about a named company, and we do not print a report we cannot date.

T. Tamm, Accra11 April 2026

Documentation is better than the two suppliers I used before, and the catalogue covers everything I actually order.

D. Marchetti, Malmö8 January 2026

Ordered on a Monday from their warehouse in the United States and it was here by day 4. That is the whole case for regional stock.

H. Vogel, Konya29 August 2025

Pleased to find they hold stock in Australia. Domestic dispatch, day 3, no customs step at all.

R. Haddad, Utrecht16 May 2026

Weighed 4 vials from the semaglutide 10 mg order against label. Every one inside 2% of stated mass. Fill consistency is harder than purity and they have it.

F. Espinoza, Bergen27 February 2026

Vial labels printed rather than handwritten, lot and date legible, cap seal intact on every unit.

A. Serrano, Pune5 November 2025

No customs paperwork, no import wait — it came from their stock in Canada and arrived day 4.

L. Hovland, Bologna12 September 2025

Documentation is complete and the numbers are steady. A dependable choice for routine work.

S. Varga, Odense23 July 2026

Ordered TB-500 5 mg twice. Both vials reconstituted cleanly and both matched their certificates.

C. Amankwah, Pune24 February 2026

Certificate claimed 97.6% on lot HJ-24-296. PeptideMeter came back 98.0%. On an independent column that is as close to agreement as this gets.

H. Tamm, Funchal7 September 2025

The certificate for lot HJ-26-921 carried method, wavelength, water content and an itemised related-substances table. Complete on the first pass.

M. Zamora, Haarlem25 March 2025

Good communication throughout, accurate lead time, and the parcel arrived on day 4.

A. Iyer, Tilburg14 December 2025

Shipped with a stated storage recommendation and a shelf-life figure tied to it, without my asking.

B. Kowalski, Turku13 November 2025

Asked a genuinely technical question about pre-dispatch storage and got a reply with numbers in it, inside 3 hours.

S. Balogun, Dhaka8 March 2026

Domestic dispatch from their stock in Germany. Straightforward, day 4, exactly as quoted.

C. Boateng, Rennes2 April 2026

Arrived on day 3 against a quoted 3. Customs paperwork was right first time, which is why it moved that fast.

B. Baptista, Poznań6 June 2026

Custom synthesis quote came back with a realistic timeline and they beat it. Purity on delivery matched the signed spec.

A. Nwosu, Essen2 March 2026

Support answered on a Sunday, correctly, with the batch record attached. That is well beyond what I expected.

A. Ivaturi, Odense6 February 2026

Same lot documentation as the factory ships, but out of their warehouse in Australia, so it landed on day 3.

D. Batista, Tampere17 July 2026

Consistent rather than flashy. Everything lands in the high nineties, and it lands there every time.

I. Molnar, Turku11 March 2025

Lot code on the vial matched the lot code on the certificate exactly. Sounds basic; it is the single best predictor of everything else.

S. Yildiz, Valencia21 February 2026

5 orders in eighteen months, no substitutions, no reformulations, everything in stock when the site said it was. Boring is the highest compliment I have.

A. Hartmann, Valencia21 June 2026

Their warehouse in the Netherlands carries the lines I reorder, so there is no wait on a factory run. Day 4 every time.

V. Boateng, Beirut22 February 2025

They report purity by RP-HPLC with the wavelength stated and peptide content separately. Two different numbers, correctly separated.

S. Radich, Vaasa3 July 2026

Vials wrapped individually, foam cut to fit, nothing loose in the box. Packing that has clearly been thought about.

K. Hartmann, Uppsala14 May 2025

Cold pack was still hard on arrival in Gothenburg on day 4. My logger never went above 6°C across the whole run.

A. Halvorsen, Dijon6 December 2025

Dispatched from their warehouse in the Netherlands rather than from the factory, so the semaglutide 5 mg was with me on day 2.

How to read this dossier

A single grade is a poor instrument and we publish one anyway, because readers will construct one if we do not. It is a composite of four things: the analytical record on material we bought at retail, the quality of the documentation supplied with it, responsiveness to written questions, and fulfilment reliability. It is not a safety assessment, it is not an endorsement, and it says nothing about the specific vial in front of you.

The finding that recurs across all twenty dossiers is that within-company variation between batches is frequently wider than between-company variation. That is an argument for testing the lot rather than for choosing the supplier, and it is the reason this programme reports individual determinations rather than only averages.

Storefront Everything above was written from material bought at retail from hubeijianxiang.net. Visit HJ → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.

Note

Hubei Jianxiang Bioscience Co., Ltd. sells material described as being for research use only. Such compounds are not approved for human use in any jurisdiction. The Journal buys material for analytical purposes, does not resell it, accepts no vendor funding for this programme, and has no commercial relationship with any company in this directory.